Technology Winners Circle - Company Profiles
Member Jennifer Kronstain
Editorial and Promotional Consultant
provides secure virtual workspaces for pharmaceutical and
financial companies around the world. Using IntraLinks' secure,
neutral third-party service, members of business communities
can share information and execute transactions in just days
where once it took weeks. No longer must the key players meet
in person, or even visit each others' offices to read reams
of paper before making a decision - now it's all done online.
With a client list that includes all ten of the top ten global
banks and six of the top ten pharmaceutical companies, the
little company that no one noticed six years ago has changed
the way some of the world's largest corporations do business.
It all began in 1997 with the first-ever online loan syndication,
conducted on IntraLinks by JP Morgan. Through hard work and
dedication, IntraLinks worked to bring the rest of the loan
syndications community online, allowing for rapid secure distribution
of confidential documents. Today, the company estimates that
over 90% of domestic loan syndications are facilitated by
its services. It has expanded its offerings throughout the
financial services industry, providing virtual data rooms
for M&A; transactions and reporting and fundraising solutions
for private equity funds.
Seeking other markets burdened with problems similar to those
in financial services brought IntraLinks to the pharmaceutical
industry. Drug development is expensive; every day that IntraLinks
helps drug companies save in development time can translate
to millions of dollars.
Now with top-tier clients in debt capital markets, life sciences,
alternative investments and mergers and acquisitions, IntraLinks
is well on its way to establishing itself as key to many corporate
The company reported $20 million in revenue for the fiscal
year ending December 31, 2002 with new contract growth at
20 percent. The company experienced significant growth in
financial services, with new offerings for alternative investments
and mergers and acquisitions, and tripled its revenue in the
life sciences market.
The bottom line: IntraLinks may never have been "the next
big thing" per se, but certainly they are "the thing" now.